Kyto Technology And Life Science Inc Revenue Growth Rates (KBPH), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Kyto Technology And Life Science Inc   (KBPH)
 

KBPH's Revenue Growth by Quarter and Year

Kyto Technology And Life Science Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

KBPH Revenue (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
4th Quarter March -
3rd Quarter December 0.00
2nd Quarter September 0.00
1st Quarter June 0.00
FY 0.00





KBPH Revenue third quarter 2022 Y/Y Growth Comment
Kyto Technology And Life Science Inc in the third quarter 2022 recorded of $ 0.00 millions.

According to the results reported in the third quarter 2022, Kyto Technology And Life Science Inc achieved the best Revenue growth in Major Pharmaceutical Preparations industry. While Kyto Technology And Life Science Inc ' s Revenue no change of 0% ranks overall at the positon no. in the third quarter 2022.


KBPH Revenue ( Y/Y Growth %) 2022
 2021 2020 2019
4th Quarter March - - - -
3rd Quarter December - - 0 % -
2nd Quarter September - - - -
1st Quarter June - - - -
FY   - - 100 % -

Financial Statements
Kyto Technology And Life Science Inc 's third quarter 2022 Revenue $ 0.00 millions KBPH's Income Statement
Kyto Technology And Life Science Inc 's third quarter 2021 Revenue $ 0.00 millions Quarterly KBPH's Income Statement


KBPH Revenue (Quarter on Quarter Growth %)

 2022
 2021 2020 2019
4th Quarter March - - - -
3rd Quarter December - - 0 % -
2nd Quarter September - - - -
1st Quarter June - - - -
FY (Year on Year)   - - 100 % -


Back to KBPH Growth rate Comparisons >> Back to KBPH Growth rate Comparisons >>


Revenue third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Revenue third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Revenue by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Kyto Technology And Life Science Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


KBPH's III. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


KBPH's III. Quarter Q/Q Revenue Comment


Kyto Technology And Life Science Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2021)		 12 Months Ending
(Sep 30 2021)		 12 Months Ending
(Jun 30 2021)		 12 Months Ending
(Mar 31 2021)		 12 Months Ending
(Dec 31 2020)
Cumulative Revenue 12 Months Ending $ 0.00 $ 0.00 $ 0.00 $ 0.00 $ 0.00
Y / Y Revenue Growth (TTM) - - - - -
Year on Year Revenue Growth Overall Ranking # # # # #
Seqeuential Revenue Change (TTM) - - - - -
Seq. Revenue Growth (TTM) Overall Ranking # # # # #


Cumulative Revenue growth Comment
In the Dec 31 2021 period, Kyto Technology And Life Science Inc 's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

Kyto Technology And Life Science Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
 0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Revenue growth Comment
In the Dec 31 2021 period, Kyto Technology And Life Science Inc 's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

Kyto Technology And Life Science Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 






Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
KBPH's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue no change for the quarter ending Dec 31 2021 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2021
Regenerx Biopharmaceuticals inc -0.01%$ -0.005 millions
Xtant Medical Holdings Inc -0.32%$ -0.321 millions
Biomarin Pharmaceutical Inc-0.51%$ -0.510 millions
Organon and Co -0.62%$ -0.620 millions
Healthcare Services Group Inc -0.65%$ -0.645 millions
Bausch Health Companies Inc -0.77%$ -0.768 millions
Tenet Healthcare Corp-1.20%$ -1.200 millions
Rockwell Medical inc -1.20%$ -1.203 millions
China Pharma Holdings Inc-1.42%$ -1.424 millions
Mimedx Group Inc -1.66%$ -1.662 millions
Adm Tronics Unlimited Inc -1.70%$ -1.703 millions
Marinus Pharmaceuticals Inc -1.75%$ -1.745 millions
Reshape Lifesciences Inc-2.00%$ -1.996 millions
Bicycle Therapeutics Plc-2.00%$ -2.001 millions
Zimmer Biomet Holdings Inc -2.27%$ -2.273 millions
Elanco Animal Health Incorporated-2.34%$ -2.343 millions
Gilead Sciences Inc -2.39%$ -2.385 millions
Axogen inc -2.95%$ -2.948 millions
Acorda Therapeutics Inc -3.12%$ -3.124 millions
Veru Inc -3.30%$ -3.297 millions
Merck and Co Inc -3.56%$ -3.564 millions
Neuronetics Inc -3.58%$ -3.575 millions
Biogen Inc -4.16%$ -4.165 millions
Inmed Pharmaceuticals Inc-4.23%$ -4.230 millions
Pharming Group N v -4.38%$ -4.378 millions
Notable Labs Ltd -4.39%$ -4.390 millions
Semler Scientific inc -4.40%$ -4.398 millions
Cv Sciences Inc -4.42%$ -4.424 millions
Meridian Bioscience Inc -4.92%$ -4.925 millions
Aclaris Therapeutics Inc -5.00%$ -5.000 millions


About Kyto Technology And Life Science Inc Revenue Growth Rates (KBPH), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.